BPC-157 vs LL-37 (Cathelicidin)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
BPC-157
Body Protection Compound-157 is a synthetic peptide derived from a protein found in human gastric juice. It has shown remarkable healing properties in research studies.
Full details →LL-37 (Cathelicidin)
LL-37 is the only human cathelicidin antimicrobial peptide. It plays crucial roles in innate immunity and has shown diverse biological activities including antimicrobial, immunomodulatory, and wound healing properties.
Full details →Side-by-Side Comparison
| Aspect | BPC-157 | LL-37 (Cathelicidin) |
|---|---|---|
| Dose Range | 250 mcg–500 mcg | 500 mcg–1.6 mg |
| Frequency | 2x daily | 1x daily |
| Cycle Length | 4–6 weeks | 2–4 weeks |
| Route | subcutaneous | topical |
| Mechanism | BPC-157 works through multiple pathways including upregulation of growth factor expression, nitric oxide system modulation, and promotion of angiogenesis. It enhances tendon-to-bone healing and supports the formation of new blood vessels. | Disrupts bacterial membranes, neutralizes endotoxins, modulates immune cell function, and promotes wound healing. Has both direct antimicrobial and immunomodulatory effects. |
| Typical Dosage | Typical research dosages range from 250-500mcg administered 1-2 times daily. Both subcutaneous and oral administration have been studied. | Research protocols vary widely. Typical ranges: 50-200mcg administered subcutaneously 2-3 times weekly. Some protocols use higher doses for acute infections. |
| Administration | Can be administered subcutaneously near the injury site or systemically. Stable in gastric juice, making oral administration viable. | Subcutaneous injection. Can cause significant injection site reactions. Often used in conjunction with other immune-supporting protocols. |
| Side Effects | Generally well-tolerated in research. Some reports of mild nausea or dizziness at higher doses. | Injection site pain and reactions are common. May cause flu-like symptoms, temporary fatigue, or immune activation responses. |
| Best For |
What They Have in Common
BPC-157, LL-37 (Cathelicidin) are both commonly used for:
Key Differences
Unique to BPC-157:
Which Has Stronger Evidence?
- Recovery & Healing: BPC-157 has stronger research support.
| Goal | BPC-157 | LL-37 (Cathelicidin) |
|---|---|---|
| Recovery & Healing | high | medium |
Key Studies
BPC-157
- Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.
HSS journal : the musculoskeletal journal of Hospital for Special Surgery, 2025
- Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing.
Current reviews in musculoskeletal medicine, 2025
- Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study.
Alternative therapies in health and medicine, 2024
LL-37 (Cathelicidin)
- Cathelicidin LL-37 Expression in Human Breast Implant Capsules.
Plastic and reconstructive surgery, 2024
- Salivary Cathelicidin (LL-37) in Children and Adolescents Living with HIV.
Biomedicine hub, 2024
- Antifungal properties of cathelicidin LL-37: current knowledge and future research directions.
World journal of microbiology & biotechnology, 2023
Ready to Learn More?
Looking for trusted sources?